Trial in Progress: A Phase 3 Randomized Study of Low-Dose Intralesional Cemiplimab Versus Primary Surgery for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma (CLEAR CSCC). J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 30];9(6):s689. Available from: https://skin.dermsquared.com/skin/article/view/3845